| Turalio (pexidartinib) / Daiichi Sankyo |
NCT02401815: CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors |
|
|
| Completed | 1b | 51 | US | PLX9486, CGT9486, Pexidartinib, PLX3397, Sunitinib | Cogent Biosciences, Inc., Plexxikon | Gastrointestinal Stromal Tumors | 05/20 | 05/20 | | |
NCT03158103: A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
|
|
| Completed | 1 | 3 | US | MEK162, Binimetinib, Pexidartinib | Memorial Sloan Kettering Cancer Center, Array BioPharma, Plexxikon | Gastrointestinal Stromal Tumor (GIST) | 04/21 | 04/21 | | |
NCT02390752: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... |
|
|
| Recruiting | 1 | 54 | US | TURALIO(R) | National Cancer Institute (NCI) | Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma | 12/25 | 12/25 | | |
